Deep Longevity, a subsidiary of Hong Kong-listed Regent Pacific Group Limited (0575.HK), launched a US consumer digital health platform called Accrua on September 28, 2026, centered on a proprietary AI tool called BloodAge that estimates a person’s biological age from routine blood work and reassesses it every quarter. The platform is set to go live across all 50 US states in October, with LegitScript certification planned before the rollout to signal compliance to telehealth partners and regulators. “The launch of Accrua is a landmark moment for Deep Longevity and for the Group,” said Jamie Gibson, Regent Pacific’s Executive Director and Chief Executive Officer, in the announcement. The launch adds another entrant to a crowded and fast-growing field of companies promising to tell consumers not how many years they’ve lived, but how quickly their bodies are actually aging.
What Biological Age Actually Measures
Chronological age simply counts birthdays. Biological age, by contrast, is an estimate derived from biomarkers, blood chemistry, inflammatory markers, organ function panels, and in some products, epigenetic DNA methylation patterns, that correlate with how fast an individual’s tissues are aging relative to population averages. Deep Longevity’s BloodAge model applies machine learning to standard blood panel results, an approach the company says makes the test more accessible and repeatable than DNA-based epigenetic clocks, since it can rely on labs most people already have done at annual physicals. The company points to a peer-reviewed study, published by Goshen and colleagues in the journal Aging and Disease in 2026, that followed roughly 2,600 adults over an average of 9.2 years and found that each additional year of gap between a person’s biological and chronological age was associated with a 15% increase in mortality risk, the evidentiary basis Deep Longevity cites for treating the score as more than a novelty number.
Accrua’s Pitch: Ongoing Tracking, Not a One-Time Snapshot
Unlike many longevity clinics that sell a single comprehensive workup costing thousands of dollars, Accrua is built around quarterly biological age measurement paired with clinician-guided treatment recommendations delivered through licensed US physicians, and, notably, compounded therapies the platform can help arrange, including GLP-1 weight-loss drugs, peptides, hormone replacement therapy, and testosterone therapies anchored to a user’s BloodAge result rather than to reported symptoms alone. The company describes its business model as capital-efficient: Accrua does not own clinical infrastructure or drug inventory itself, instead routing care through established telehealth partners, and it expects revenue to be largely subscription-based and recurring. That subscription-style model mirrors a broader shift in the longevity diagnostics market, which analysts project will grow from roughly $2.9 billion in 2025 toward $5.58 billion by 2030, driven by AI-powered multi-omics diagnostics, at-home testing kits, and wearable integration.
A Market That Is Already Getting Crowded
Accrua enters a field that includes established players like Elysium Health, InsideTracker, and TruDiagnostic, all of which have built businesses around biological age testing and personalized supplement or lifestyle recommendations. Thrive Global launched its own multi-omics Elite Longevity Assessment earlier this year, combining biomarker panels with metabolic profiling and AI-generated healthspan forecasts. Waitlists at longevity clinics have stretched into months, and direct-to-consumer epigenetic testing kits have reportedly sold faster than manufacturers projected, evidence of genuine consumer appetite even before questions about the science are fully settled. Regent Pacific has pointed to MEDVi, a comparable consumer telehealth platform, which generated more than $400 million in revenue in 2025 and is tracking toward a $1.8 billion run-rate in 2026, as a sign of how quickly a subscription-based longevity platform can scale once it has regulatory and clinical infrastructure in place.
The Skeptics’ Case
Biological age tests occupy an unusual regulatory position: the FDA does not regulate them as diagnostic devices, treating them more like consumer genetic ancestry kits than clinical tools. Researchers at Stanford and elsewhere have cautioned that biological age scores, however scientifically grounded the underlying biomarkers may be, should be interpreted with real caution rather than certainty, since a single number can mask enormous variability in how different organ systems age independently, and because algorithms trained primarily on one demographic may generalize poorly to others. Critics also note that a favorable biological age reading tied to a company’s own supplement or therapy recommendations creates an obvious incentive structure worth scrutinizing, particularly when the same platform that issues the score also profits from prescribing GLP-1s, peptides, or hormone therapy in response to it.
Recognition and Backing
Deep Longevity’s BloodAge technology was named runner-up in Nestlé’s VITAL Smart Aging Global Challenge, a competition that drew roughly 150 competing companies, lending the platform a degree of outside validation beyond its own peer-reviewed research. Regent Pacific has not disclosed pricing for Accrua subscriptions, and the company has cautioned investors that resulting revenues remain uncertain and will depend on consumer demand, competitive dynamics, and the regulatory environment for telehealth and compounded medications. Initial rollout is planned through targeted digital marketing in select states rather than a nationwide advertising push, a cautious go-to-market approach that suggests the company is still testing demand before committing to larger-scale customer acquisition spending.
What to Watch as the Category Matures
The immediate test for Accrua and its competitors will be whether quarterly retesting actually demonstrates that a person’s biological age score improves in response to lifestyle changes or prescribed therapies, evidence that would meaningfully differentiate the category from expensive placebo. Longer term, the bigger prize industry insiders are chasing is a validated biological age metric accepted broadly enough by clinicians and insurers to influence actual treatment decisions, not just consumer curiosity, a bar the field has not yet cleared despite years of rapid commercial growth. In the meantime, Accrua’s compounded-therapy offering is likely to draw particular scrutiny from state pharmacy boards and the FDA, since compounded medications sold alongside a proprietary risk score raise the same conflict-of-interest questions that have already dogged other longevity clinics accused of using test results to upsell expensive, unproven interventions rather than simply reporting a number back to a patient’s own physician.
Photo: Tima Miroshnichenko / PEXELS via Pexels
